Prism Medico & Pharmacy Ltd (PRISMMEDI) — shareholding pattern, promoter holding, financials and share price
About Prism Medico & Pharmacy Ltd (PRISMMEDI)
Prism Medico & Pharmacy Ltd operates in the Non Banking Financial Company (NBFC) industry, within the Financial Services sector. It trades on the NSE as PRISMMEDI and on the BSE under scrip code 512217. Its ISIN is INE730E01016.
Incorporated in 1985, Prism Medico & Pharmacy Ltd manufactures, trades, and distributes chemicals, medicines, pharmaceuticals, cosmetics, and related products [1]
Prism Medico and Pharmacy Limited was originally founded in 1985 and engaged in wholesale and retail of animal feed before switching to pharmaceuticals and related products in 2022-23.
Since the transition, the company has expanded its core business to include pharmaceuticals, drugs, nutraceuticals, healthcare products, and dietary supplements, signifying a strategic pivot in its operations.
Listed peers in Non Banking Financial Company (NBFC): Continental Securities Ltd, Kiduja India Ltd, Sugal & Damani Share Brokers Ltd, HB Stockholdings Ltd, Glance Finance Ltd, Amit Securities Ltd.
Valuation & Returns
10 Jul 2026At ₹28.8 a share on 10 Jul 2026, Prism Medico & Pharmacy Ltd (PRISMMEDI) was valued at a price-to-earnings ratio of 118.36x against an industry P/E of 19.5x and a price-to-book of 3.03x on a book value of ₹9.52 per share as of Mar 2019. Solomo computes return on equity of -4.27% and return on capital employed of -2.84% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2019 to Dec 2019.
- P/E
- 118.36x
- Industry P/E
- 19.5x
- P/B
- 3.03x
- EPS (TTM)
- ₹-0.41
- Book value / share
- ₹9.52
- ROE
- -4.27%
- ROCE
- -2.84%
- ROA
- -2.6%
- Debt / equity
- 0.18x
- Dividend yield
- 0%
- EBITDA margin
- 18.03%
- 52-week range
- ₹12.49 – ₹34.49
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2019In the year ended Mar 2019, Prism Medico & Pharmacy Ltd (PRISMMEDI) reported revenue of ₹54.43 crore, net profit of ₹0.04 crore and earnings per share of ₹0.07. That compares with revenue of ₹22.78 crore in Mar 2018. Figures are consolidated, as filed with the exchanges.
In the quarter ended Dec 2019, revenue was ₹9.75 crore and net profit ₹-0.04 crore (consolidated).
| Metric | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|
| Revenue (₹ cr) | 5.27 | 22.78 | 54.43 |
| Net profit (₹ cr) | -0.22 | 0 | 0.04 |
| EPS (₹) | -0.36 | 0 | 0.07 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 24.96% | -52.77% | -57.86% | 138.73% |
| Stock price CAGR | 3% | 32% | 7% | 102% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 29.98% of Prism Medico & Pharmacy Ltd (PRISMMEDI) (up 4.49 pp QoQ). Market capitalisation was ₹39 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Dharmender Kharb 19.35%, Raju Tyagi 9.77%, Sejal S Nashatar 2.51%, Shilpa Harsh Rupareliya 2.43%, Harsh Jentibhai Rupareliya 2.43%, ANSHUL JAJOO 1.4%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 29.98% | - | - | - | 70.02% |
| Mar 2026 | 25.49% | - | - | - | 74.51% |
| Dec 2025 | 25% | - | - | - | 75% |
| Sep 2025 | 25% | - | - | - | 75% |
| Jun 2025 | 25% | - | - | - | 75% |
| Mar 2025 | 25% | - | - | - | 75% |
| Dec 2024 | 25% | - | - | - | 75% |
| Sep 2024 | 25% | - | - | - | 75% |